The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA

Open source

DOI: 10.1038/s41591-023-02593-0
Published: 2023 Nov
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-023-02593-0,
  title = {The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.},
  author = {Luke JJ and Patel MR and Blumenschein GR and Hamilton E and Chmielowski B and Ulahannan SV and Connolly RM and Santa-Maria CA and Wang J and Bahadur SW and Weickhardt A and Asch AS and Mallesara G and Clingan P and Dlugosz-Danecka M and Tomaszewska-Kiecana M and Pylypenko H and Hamad N and Kindler HL and Sumrow BJ and Kaminker P and Chen FZ and Zhang X and Shah K and Smith DH and De Costa A and Li J and Li H and Sun J and Moore PA},
  year = {2023},
  journal = {Nature medicine},
  doi = {10.1038/s41591-023-02593-0},
  url = {https://doi.org/10.1038/s41591-023-02593-0}
}

RIS

TY  - JOUR
TI  - The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
AU  - Luke JJ
AU  - Patel MR
AU  - Blumenschein GR
AU  - Hamilton E
AU  - Chmielowski B
AU  - Ulahannan SV
AU  - Connolly RM
AU  - Santa-Maria CA
AU  - Wang J
AU  - Bahadur SW
AU  - Weickhardt A
AU  - Asch AS
AU  - Mallesara G
AU  - Clingan P
AU  - Dlugosz-Danecka M
AU  - Tomaszewska-Kiecana M
AU  - Pylypenko H
AU  - Hamad N
AU  - Kindler HL
AU  - Sumrow BJ
AU  - Kaminker P
AU  - Chen FZ
AU  - Zhang X
AU  - Shah K
AU  - Smith DH
AU  - De Costa A
AU  - Li J
AU  - Li H
AU  - Sun J
AU  - Moore PA
PY  - 2023
JO  - Nature medicine
DO  - 10.1038/s41591-023-02593-0
UR  - https://doi.org/10.1038/s41591-023-02593-0
ER  -

APA

JJ, L., MR, P., GR, B., E, H., B, C., SV, U., RM, C., CA, S., J, W., SW, B., A, W., AS, A., G, M., P, C., M, D., M, T., H, P., N, H., HL, K., BJ, S., P, K., FZ, C., X, Z., K, S., DH, S., A, D. C., J, L., H, L., J, S., & PA, M. (2023). The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.. Nature medicine. https://doi.org/10.1038/s41591-023-02593-0

Source records

pubmed · retrieved 2026-09-26T09:43:51.780Z